Protocol: ECOG – EAY191 -E4
Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss the complete list of eligibility.
Eligibility:
- Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration to the EAY191-E4 study.
- Patient must be ≥ 18 years of age.
- Patient must not have any of the following mutations (as determined by the ComboMATCH Registration Protocol), which are known to confer sensitivity or resistance to nilotinib monotherapy: KIT: W557R, V559D, V559A, L576P, and K642E, PDGFR-α: D842V.
- Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to the date of registration.
- Patient must have had at least one prior line of therapy in the metastatic setting.
- Patient must have previously undergone taxane therapy (in the metastatic setting).
- Patient must have an ECOG Performance Status of 0-2.
- Patient must not have had platinum-resistant epithelial serous ovarian cancer.
- Patient must not have peripheral neuropathy > grade 1.
- Patients must not have neuropathy ≥ grade 2 within 14 days of registration/randomization.
- Patient must have documented QT interval with Fridericia’s correction (QTcF) of ≤ 450 msec within 8 days prior to EAY191-E4 registration. Patients with a QTcF interval of ≥450 msec at registration or patients with congenital long QT syndrome are not eligible.